Research progress on the role and clinical application of Siglecs in tumor immunity.
- Author:
Hui CHEN
1
;
Jialin LU
1
;
Danru WANG
1
;
Lihao SUI
1
;
Sheng XU
2
Author Information
1. National Key Laboratory of Medical Immunology, The Second Military Medical University, Shanghai 200082, China.
2. National Key Laboratory of Medical Immunology, The Second Military Medical University, Shanghai 200082, China. *Corresponding author, E-mail: xusheng@immunol.org.
- Publication Type:Journal Article
- MeSH:
Sialic Acid Binding Immunoglobulin-like Lectins/metabolism*;
N-Acetylneuraminic Acid;
Immunoglobulins/metabolism*;
Receptors, Immunologic;
Ligands
- From:
Chinese Journal of Cellular and Molecular Immunology
2023;39(12):1125-1131
- CountryChina
- Language:Chinese
-
Abstract:
Lectins are proteins responsible for recognizing the signals of sugar molecules in the body. Sialic acid-binding immunoglobulin-like lectins (Siglecs) regulate the innate and adaptive immune responses in the tumor microenvironment by recognizing the glycan structure containing sialic acid and mediating downstream signals through immune receptor tyrosine inhibitory motifs. In recent years, a variety of tumor treatment strategies targeting the sialic acid-Siglecs axis have been introduced, including sialoglycoprotein-mediated drug delivery and antibody mediated inhibition of Siglecs from recognizing tumor surface ligands. In the future, by combining with glycoprotein nanotherapy, antibody therapy and gene therapy, Siglecs can be used to accurately locate tumor targets and release the anti-tumor immunity, so as to achieve the purpose of effective cure of tumors.
